All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your GvHD Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

TRANSLATE

The GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering Committee About Us Newsletter Contact

Visit:

You're logged in! Click here any time to manage your account or log out.

Steering Committee About Us Newsletter Contact

Brought to you by

The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Types Therapeutics Congresses Trials Expert Opinions Educational Resources DRUG UPDATES

GvHD Types

2020-12-15T10:13:09.000Z

What plasma short-chain fatty acids are predictors of response to GvHD therapy?

By Paola Frisone, Megan Lee

Featured

Shernan Holtan

Dec 15, 2020

Bookmark this article

Video series

ASH 2020: the microbiome and GvHD

1

3:13

Is the microbiota biotherapeutic MaaT013 a safe and effective option for...

Florent Malard

2

2:24

What is the evidence that fecal microbiota transplantation can cure GvHD?

Mette Hazenberg

1:45

What plasma short-chain fatty acids are predictors of response to GvHD...

Shernan Holtan

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub spoke to Shernan G. Holtan, University of Minnesota, Minneapolis, US. We asked, What plasma short-chain fatty acids are predictors of response to graft-versus-host disease therapy?

Holtan describes the results of a clinical trial evaluating how acute GvHD treatment response relates to plasma levels of short-chain fatty acids. In general, levels of butyrate are higher in patients responding to therapy.